1291487-26-7 Usage
Uses
Used in Organic Synthesis:
5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic and agricultural applications.
Used in Dye and Pigment Production:
5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde also serves as an intermediate in the production of dyes and pigments, where its specific chemical properties contribute to the development of colorants with distinct characteristics.
Used in Medicinal Chemistry:
Due to its unique chemical structure, 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde has potential applications in medicinal chemistry. It can be used to develop new drugs with novel mechanisms of action or improved pharmacological properties.
Used in Material Chemistry:
In the field of material chemistry, 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde may be employed to create new materials with specific properties, such as improved stability or reactivity, which can be beneficial in various industrial applications.
Overall, 5-Bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde is a versatile chemical with applications across multiple industries, including pharmaceuticals, agrochemicals, dyes and pigments, and material chemistry, making it an important compound in organic chemistry research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1291487-26-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,9,1,4,8 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1291487-26:
(9*1)+(8*2)+(7*9)+(6*1)+(5*4)+(4*8)+(3*7)+(2*2)+(1*6)=177
177 % 10 = 7
So 1291487-26-7 is a valid CAS Registry Number.
1291487-26-7Relevant academic research and scientific papers
INHIBITING HUMAN INTEGRIN α4β7
-
Page/Page column 163; 217, (2021/04/23)
Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.
TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00273, (2020/11/30)
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis
COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00297, (2020/12/01)
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.
IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00333, (2019/05/30)
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
IRE1 SMALL MOLECULE INHIBITORS
-
Paragraph 00257, (2019/01/05)
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
